New aspects of cyclooxygenase-2 inhibition in myocardial infarction and ischaemia

Research Communications in Molecular Pathology and Pharmacology

Volumn 117-118, Issue , 2005, Pages 167-178

  Saeed, Sheikh Arshad ^a   Ahmed, S ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

adrenergic agonist; Coagulation necrosis; Collagen deposition; Creatinine phosphokinase (CPK); Cyclooxygenase 2 (COX 2); Electrocardiographic (ECG) changes; Heavy interstitial infiltrate; Histochemical studies; Ischemia; Isoprenaline (ISP)

Indexed keywords

COLLAGEN; CREATINE KINASE; CYCLOOXYGENASE 2; ISOPRENALINE; NIMESULIDE; TROPONIN I;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; ELECTROCARDIOGRAPHY; ENZYME BLOOD LEVEL; ENZYME INDUCTION; ENZYME INHIBITION; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HISTOCHEMISTRY; HISTOPATHOLOGY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; Q WAVE; RABBIT; ST SEGMENT ELEVATION;

ADRENERGIC BETA-AGONISTS; ANIMALS; CARDIOTONIC AGENTS; CREATINE KINASE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; ELECTROCARDIOGRAPHY; ISOPROTERENOL; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NECROSIS; RABBITS; SULFONAMIDES; TROPONIN I;

EID: 40549112658     PISSN: 10780297     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Adams, J.E. 3rd., Bodor, G.S., Davila-Roman, V.G., Delmez, J.A., Apple, F.S., Ladenson, J.H. and Jaffe, A.S. (1993). Cardiac troponin I: a marker with high specificity for cardiac injury. Circulation. 88, 101-106.
2. Baker, C.S., Hall, R.J., Evans, T.J., Pomerance, A., Maclouf, J., Creminon, C., Yacoub, M.H. and Polak, J.M. (1999). Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalized with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb. Vasc. Biol. 19, 646-655.
3. Belton, O., Byrne, D., Kearney, D., Leahy, A. and Fitzgerald, D.J. (2000). Cyclooxygenase-1 and -2 dependent prostacyclin formation in patients with atherosclerosis. Circulation. 102, 840-845.
4. Bevilacqua, M., Vago, T., Baldi, G., Renesto, E., Dallegri, F. and Norbiato, G. (1994). Nimesulide decreases superoxide produciotn by inhibiting phosphodiesterase type IV. Eur. J. Pharmacol. 268, 415-423.
5. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M.B., Hawkey, C.J., Hochberg, M.C., Kvien, T.K. and Schnitzer, T.J. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N. Engl. J. Med. 243, 1520-1528.
6. Bonow, R.O., Lipson, L.C., Shaheen, F.H., Capurro, N.L., Inser, J.M., Roberst, W.C., Goldstein, R.E. and Epstein, S.E. (1981). Lack of effect of aspirin on myocardial infarct size in dogs. Am. J. Cardiol. 47, 258-264.
7. Cai, H. and Harrison, D.G. (2000). Endothelial dysfunction in cardiovascular disease: the role of oxidant stress. Cirs. Res. 87, 840-844.
8. Capecchi, P.L., Ceccatelli, L., Beermann, U., Laghi-Pasini, F. and Di-Perri, T. (1993). Inhibition of neutrophil function in vitro by nimesulide. Preliminary evidence of an adenosine-mediated mechanism. Arzneimittelforschung. 43, 992-996.
9. Chenevard, R., Hurlimann, D., Bechir, M., Enseleit, F., Spieker, L., Hermann, M., Riesen, W., Gay, S., Gay, R.E., Neidhart, M., Michel, B., Luscher, T.F., Noll, G. and Ruschitzka, F. (2003). Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 107, 405-409.
10. Fletcher, P.J., Pfeffer, J.M., Pfeffer, M.A. and Braunwald, E. (1980). Myocardial infarction in experimental hypertension in rats: mechanism of the reduction in blood pressure. Clin. Sci. (Lond). 59, 385s-387s.
11. Frolich, J.C. (1997). A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends. Pharmacol. Sci. 18, 30-34.
12. Heitzer, T., Just, H. and Munzel, T. (1996). Antioxidant viamin C improves and endothelial dysfunction in chronic smokers. Circulation. 94, 6-9.
13. Lecomte, M., Laneuville, O., Ji, C., DeWitt, D.L. and Smith, WL. (1994). Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J. Biol. Chem. 269, 13207-13215.
14. Mukerjee, D. (2002). Selective Cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem. Pharmacol. 63, 817-821.
15. Mukerjee, D., Nissen, S.E. and Topol, E.J. (2001). Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 286, 954-959.
16. O, Banion, M. (1999). Cyclooxygenase-2: Molecular biology, pharmacology and neurobiology. Critc. Rev. Neurobiol. 13, 45-82.
17. Rosalki, S.B. (1967). An improved procedure for serum creatine phosphokinase determination. J. Lab. Clin. Med. 69, 696-705.
18. Saeed, S.A., Gilani, A.H., Sultan, B.H., Karim, R.M. and Shah, B.H. (1998). Myocardial ischemia and infarction in isoprenaline-treated rabbits: Role of cyclooxygenases. Bichem. Soc. Trans. 26, S342.
19. th World Congress on Inflammation.
20. Saito, T., Rodger, I.W., Hu, F., Shennib, H. and Giaid, A. (2000). Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem. Biphys. Res. Commun. 273, 772-775.
21. Schonbeck, U., Sukhova, G.K., Graber, P., Coulter, S. and Libby, P. (1999). Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J. Pathol. 155, 1281-1291.
22. Silverstein, F.E., Faich, G., Goldstein, J.L., Simon, L.S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N.M., Stenson, W.F., Burr, A.M., Zhao, W.W., Kent, J.D., Lefkowith, J.B., Verburg, K.M. and Geis, G.S. (2000). Gastrointestinal toxicity with celecoxib vs nonsterodial anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS Study. A randomized control trial. JAMA. 284, 1247-1255.
23. Tool, A.T. and Verhoeven, A.J. (1995). Inhibition of the production of platelet activating factor and of leukotriene B4 in activated neutrophils by nimesulide due to an elevation of intracellular cyclic adenosine monophosphate. Arzeimittelforschung. 5, 1110-1114.
24. Tool, A.T., Mul, F.P., Knol, E.F., Verhoeven, A.J. and Roos, D. (The effect of salmeterol and nimesulide on chemotaxis and synthesis of PAF and LTC4 by human eosinophils. Eur. Respir. J. Suppl. 22, 141s-145s.
25. Koenig, W. (2001). Inflammation and coronary heart disease: an overview. Cardiol. Rev. 9, 31-35.
26. Young, J.M., Panah, S., Satchawatcharaphong, C. and Cheung, P.S. Human Whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm Res 1996. 45: 246-253.